These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1174 related articles for article (PubMed ID: 1746296)

  • 1. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
    Wilt TJ; Rubins HB; Collins D; O'Connor TZ; Rutan GH; Robins SJ
    Arch Intern Med; 1996 Jun; 156(11):1181-8. PubMed ID: 8639012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.
    Connelly PW; Petrasovits A; Stachenko S; MacLean DR; Little JA; Chockalingam A
    Can J Cardiol; 1999 Apr; 15(4):428-33. PubMed ID: 10322252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II.
    McNicoll S; Latour Y; Rondeau C; Bouthillier D; Davignon J; Genest J
    Can J Cardiol; 1995 Feb; 11(2):109-16. PubMed ID: 7866933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid risk factors of coronary heart disease during longterm observation of a Warsaw Pol-Monica population-based cohort].
    Chotkowska E; Jasiński B; Kupść W; Broda G
    Pol Arch Med Wewn; 1997 Jan; 97(1):37-46. PubMed ID: 9235550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.
    Krumholz HM; Seeman TE; Merrill SS; Mendes de Leon CF; Vaccarino V; Silverman DI; Tsukahara R; Ostfeld AM; Berkman LF
    JAMA; 1994 Nov; 272(17):1335-40. PubMed ID: 7772105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol.
    Stefanick ML; Mackey S; Sheehan M; Ellsworth N; Haskell WL; Wood PD
    N Engl J Med; 1998 Jul; 339(1):12-20. PubMed ID: 9647874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
    Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
    J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
    Averna M; Zaninelli A; Le Grazie C; Gensini GF
    J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
    McKenney JM; Barnett MD; Wright JT; Proctor JP
    Arch Intern Med; 1992 Sep; 152(9):1781-7. PubMed ID: 1520045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.